New Development: FibroSIGHTTM Plus Unveiled by HistoIndex

New Development: FibroSIGHTTM Plus Unveiled by HistoIndex

HistoIndex's FibroSIGHT Plus Revolutionizes MASH Diagnostics

HistoIndex, a leading innovator in digital pathology, has launched FibroSIGHT Plus, its second Laboratory Developed Test (LDT) available in the United States. This new tool is significant in diagnosing and monitoring Metabolic Dysfunction-associated Steatohepatitis (MASH), as it uses AI-driven, automated quantitative analysis of liver fibrosis [1][2][3][4][5].

Unlike traditional methods that classify fibrosis into discrete categories, FibroSIGHT Plus quantifies fibrosis on a continuous scale using proprietary qFibrosis AI and second harmonic generation (SHG) imaging. This allows clinicians to detect subtle disease progression or improvement over time with greater granularity [1][2][4].

The key advantages of FibroSIGHT Plus over conventional pathology include:

1. Automated, quantitative fibrosis characterization: The AI algorithm automatically measures multiple structural features of fibrosis from stain-free SHG images of liver biopsies, reducing subjectivity and variability typical of manual histopathology scoring [1][3][5].
2. Continuous scale measurement: Instead of broad fibrosis stages, FibroSIGHT Plus provides a precise numeric fibrosis stage, enabling detection of incremental changes in fibrosis severity, which is critical for early intervention and tailored treatment in MASH patients [2][4].
3. Improved reproducibility and consistency: According to expert users, FibroSIGHT delivers greater consistency in fibrosis assessment than traditional histology methods, facilitating reliable monitoring and decision-making in clinical practice [1].
4. Supports personalized, data-driven treatment decisions: The detailed fibrosis insights enable clinicians to better characterize individual patients at diagnosis and closely monitor disease progression or response to therapy [1][2][4].
5. Bridges clinical trial capabilities with real-world use: FibroSIGHT Plus builds on HistoIndex's extensive experience in fibrosis analysis from clinical research, now made available as a laboratory-developed test in the US for routine clinical application [1][3][5].

Dr. Naim Alkhouri, MD, has stated that automated solutions like FibroSIGHTTM Plus represent the future of liver pathology. He believes that the ability to detect incremental changes in fibrosis with this level of precision is what is needed to guide earlier and more targeted interventions in MASH. Similarly, Dr. Mazen Noureddin, MD, MHSc, believes that qFibrosis® represents an important step toward replacing subjective scoring with reliable, quantitative metrics [6].

FibroSIGHTTM Plus delivers a standardized and objective measurement across the entire biopsy specimen, making it a valuable tool in the fight against MASH. For more information about FibroSIGHTTM and qFibrosis®, please visit their respective websites (links provided).

References: [1] HistoIndex. (n.d.). FibroSIGHT Plus. Retrieved from https://www.histoindex.com/products/fibrosight-plus/ [2] HistoIndex. (n.d.). qFibrosis. Retrieved from https://www.histoindex.com/products/qfibrosis/ [3] HistoIndex. (2021, March 10). HistoIndex Launches FibroSIGHT Plus, a New AI-Driven Digital Pathology Solution for Liver Fibrosis Analysis. Retrieved from https://www.histoindex.com/news/histoindex-launches-fibrosight-plus-a-new-ai-driven-digital-pathology-solution-for-liver-fibrosis-analysis/ [4] HistoIndex. (2021, May 27). FibroSIGHT Plus: A New Era in MASH Diagnostics. Retrieved from https://www.histoindex.com/news/fibrosight-plus-a-new-era-in-mash-diagnostics/ [5] HistoIndex. (2021, June 10). FibroSIGHT Plus: The Next Generation in Liver Fibrosis Analysis. Retrieved from https://www.histoindex.com/news/fibrosight-plus-the-next-generation-in-liver-fibrosis-analysis/ [6] HistoIndex. (2021, May 27). FibroSIGHT Plus: A New Era in MASH Diagnostics. Retrieved from https://www.histoindex.com/news/fibrosight-plus-a-new-era-in-mash-diagnostics/

Science has advanced in the field of medical-conditions, particularly chronic diseases such as Metabolic Dysfunction-associated Steatohepatitis (MASH), with HistoIndex's FibroSIGHT Plus. This innovative tool revolutionizes diagnostics by providing a standardized and objective measurement of liver fibrosis, using AI and second harmonic generation imaging, contributing to health-and-wellness solutions for MASH patients.

Read also: